2017 NCCN Case Manager and Medical Director Program: Updates in the Diagnosis and Treatment of B-cell Non-Hodgkin’s Lymphoma

October 23, 2017

Join Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, as he presents Updates in the Diagnosis and Treatment of B-cell Non-Hodgkin’s Lymphoma as part of the NCCN 2017 Oncology Case Manager and Medical Director Program Webinar Series.

A better understanding of the underlying pathogenesis, identification of new targets, and the development of novel targeted therapies have significantly improved the diagnosis and management of B-cell NHLs. These recent advances underscore the importance of individualizing therapy based on the subtype, natural history of disease, and patient-related factors such as age, performance status, and the presence of comorbidities. Identification of patients at higher risk for developing treatment-related side effects, careful monitoring for any signs and symptoms immediately after initiation of treatment, and implementation of appropriate supportive care interventions are critical to improve clinical outcomes and quality of life.

Target Audience

This program is designed to meet the educational needs of case managers, nurses in other roles (i.e., quality management and utilization review), medical directors at managed care organizations, reinsurers, TPAs, and case management and disease management companies who interact with, counsel, and refer patients with cancer to appropriate sources of care and/or make coverage decisions. Programs may also be of interest to nurses, nurse navigators/care coordinators, and physicians who work directly with patients in clinical settings as well as clinical pharmacists in managed care organizations and other settings.

Learning Objectives

Following this activity, participants should be able to:

  • Identify the challenges involved in the diagnosis and management of patients with B-cell NHLs.
  • Summarize the recommendations outlined in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) B-Cell Lymphoma Guidelines for the management of various subtypes of B-cell NHL.
  • Review the treatment-related toxicities and develop an effective supportive care plan to monitor and manage potential side effects in patients with B-cell NHLs.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas and Medivation, Inc., a Pfizer Company
  • AstraZeneca
  • Genentech
  • Genomic Health, Inc.
  • Olympus Corporation of the Americas
  • Taiho Oncology
  • Takeda Oncology

This activity is supported by independent educational grants from AbbVie and Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.25 CCM clock hours
  • 1.25 ACPE contact hours
  • 1.25 ANCC contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Participation
Course opens: 
09/05/2017
Course expires: 
12/22/2017
Event starts: 
10/23/2017 - 12:00pm
Event ends: 
10/23/2017 - 1:15pm
Cost:
$0.00

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 hour of Category I credits for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.25 contact hours.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program. If approved, Activity Code and Approval Number will be posted prior to activity date.

Pharmacists

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. Universal Activity Number (UAN) will be posted prior to activity date.

Available Credit

  • 1.25 CCM clock hours
  • 1.25 ACPE contact hours
  • 1.25 ANCC contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Participation

Accreditation Period

Course opens: 
09/05/2017
Course expires: 
12/22/2017

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this live webinar.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing